Checking Heart MRI Scans Against Standard Blood Tests in Heart Disease
Compares a new heart MRI method with blood tests in adults with heart conditions.
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- Longitudinal Validation of CIRC Technologies
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 6 May 2026
- Expected to end
- Aug 2037
- Type of study
- Observational, 2 groups
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults, both people with heart and blood vessel diseases and healthy people, who can have a heart MRI scan.
- Age
- 18 years or older
- Sex
- Men and women
Main reasons for not taking part
- Prisoners
- Other reasons that rule out a heart MRI scan (CMR), based on standard MRI rules
- People who cannot make their own decisions, for example because of dementia or cognitive disability
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age ≥ 18 years of age
- Provision of written informed consent
Who cannot take part
- Decisionally impaired (e.g., dementia or cognitive disability)
- Vulnerable populations will be excluded from this study including Prisoners
- Other contraindications to CMR imaging to be determined by standard MRI protocols
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Research Coordinator Research CoordinatorTaking people
About the trial
What the trial wants to find out
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.
Read full original descriptionShow less
The study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.
The 2 groups in the trial
- Healthy Volunteer
Subjects without cardiovascular disease
- Cardiovascular Disease Patients
Patients with known or suspected cardiovascular disease
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Longitudinal Validation of CIRC Technologies
- Plain-language title
- Checking Heart MRI Scans Against Standard Blood Tests in Heart DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 July 2026